Susan Baumgarten has over 30 years of experience in life science research and strategy consulting building upon her early career in marketing and patient care. Susan co-founded Aptis after two decades of research and strategy work involving nearly every therapeutic category for early-stage technologies, drugs, devices and diagnostics. Over the course of her consulting career she has completed hundreds of projects helping clients navigate commercial uncertainty, culminating in successful partnering and licensing deals and market-driven product development and positioning strategies.
Prior to co-founding Aptis Partners, she was a Senior Vice President of Kendall Strategies (Feinstein Kean Healthcare), where she established, grew, and managed the commercial research and strategy practice. Earlier in her career she held marketing roles for National Medical Care (Fresenius), where she held product development and marketing positions. She began her career as a registered dietitian at Brigham and Women’s Hospital, where she established and led clinical and public health nutrition programs.
Tucker Swan’s experience spans the pharmaceutical and medical device industry, including roles in consulting, business planning, publishing, and pharmaceutical research. Besides co-founding Aptis Partners, his consulting experience includes The Wilkerson Group, where he focused on cardiovascular devices in his role as Director of Devices for the Company’s Cardiovascular Market Intelligence Service, and as Vice President at Kendall Strategies. He has completed hundreds of projects for clients in the pharma, biotech, medical device, and diagnostic industry, spanning a range of technology evaluations, acquisition analyses, market opportunity assessments, and strategic planning studies.
Prior experience includes roles as Editor of IN VIVO: The Business and Medicine Report as well as a news reporter for MDDI Reports (“The Gray Sheet”). He has held business planning positions in the international pharmaceuticals division at Eli Lilly and Company, the domestic business planning group responsible for Eli Lilly’s diversification into the medical device and diagnostic industry, and with Therics, a start-up company developing a 3D printing process for making medical devices, tissue healing matrices, and drug delivery systems. Tucker started his career as a bench chemist at Squibb Corporation.
Principal, Entwistle Consulting
Amy Entwistle specializes in business strategy, market research, and competitive analysis for early stage pharmaceutical products and medical devices as well as discovery technologies. Her in-depth business and medical experience are derived from hundreds of interviews with physicians, scientists, and thought leaders across a broad range of therapeutic areas as well as analysis of the basic science and clinical literature and industry databases. She has a Master’s degree in Cellular and Molecular Physiology and has worked closely with the partners of Aptis since the firm was founded in 2001. She was previously a Senior Consultant with Kendall Strategies.
Principal Partner, Strategic Biomedical Consultants
Jeanne Bertonis is a seasoned healthcare professional with experience in early stage start-up companies as well as established corporations. For the last 10 years she has been providing strategic and business consulting to pharmaceutical, medical device, biomaterial, and diagnostic companies. Projects range from the creation of businesses and product and marketing strategies to licensing, partnering, and mergers and acquisitions.
She is the co-founder and CEO of Visgo Therapeutics, which focuses on local drug therapies for joint diseases. Previously, she was President and CEO of BioSyntech, a public biomaterials company with an approved product for cartilage repair, and as President and COO of Clera, a private company developing drugs for various neurological diseases. She has held the positions of Chief Business Officer and Vice President Corporate Development for Angiotech Pharmaceuticals and as Senior Director, Corporate Development at Genzyme. Additional experience includes responsibility for the Business Development group for Guidant's Vascular Intervention Division, in business and research positions with Eli Lilly and Biogen, and as Director for both private and public biotech and device companies.
EDWARD BERGER, PhD
Larchmont Strategic Advisors
Larchmont Strategic Advisors helps life sciences companies create and implement integrated strategies to address the many policy and regulatory obstacles and opportunities they face in their efforts to secure public and private insurer coverage and optimal reimbursement for new or evolving technologies. Edward Berger has more than 30 years of experience working in senior management or as a consultant with medical device, biotechnology, and health services companies, dealing with problems at the intersection of U.S. and international health care policy, corporate strategy development, and strategically sensitive corporate communications with government, investors, and the media.